] . (2009). Infliximab for the Treatment of Active Scleritis. Can J Ophthalmol, 44, e9-e12. presented at the 06/2009. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/19506593
. (2007). A Double-Masked, Randomized Study to Investigate the Safety and Efficacy of Daclizumab to Treat the Ocular Complications Related to Behçet's Disease. Ocul Immunol Inflamm, 15, 63-70. presented at the 03-04/2007. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/17558830
. (2006). Randomized Cinical Trial of Vitamin E in the Treatment of Uveitis-Associated Macular Edema. Am J Ophthalmol, 141, 193-194. presented at the 01/2006. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/16386999
. (2005). Initial Evaluation of Subcutaneous Daclizumab Treatments for Noninfectious Uveitis: A Multicenter Noncomparative Interventional Case Series. Ophthalmology, 112, 764-770. presented at the 05/2005. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/15878055
. (2004). Uveitis therapy: a phase II study using subcutaneously administered daclizumab. presented at the 2004.
. (2003). Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J Autoimmun, 21, 283-293. presented at the 2003.
. (2003). Subcutaneously administered daclizumab (SC-DAC, humanized anti-IL-2 receptor antibody) therapy for uveitis. presented at the 2003.
. (2000). The use of monoclonal therapy in the treatment of intraocular inflammatory disease. presented at the 2000.
. (1999). Discontinuation of ant cytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA, 282, 1633-37. presented at the 1999.
. (1999). Treatment of noninfectious intermediate and posterior uveitis with the humanized anti-Tac mAb: A phase I/II clinical trial. Proceedings of the National Academy of Science USA, 96, 7462-66. presented at the 1999.